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Abstract
Currently and worldwide, a high prevalence of obesity, obesity-associated metabolic
dysfunction,  and vitamin  D (VD)  deficiency  occurs.  Besides  participating  in  bone
mineralization and calcium homeostasis,  VD has other major functional roles.  The
vitamin D receptor (VDR) signaling pathway is crucial for the proper functioning of
adipose  tissue  (AT).  AT  is  a  reservoir  for  VD  and  can  activate/inactivate  VD  by
hydroxylation. Subcutaneous and visceral AT (SAT, VAT) have different and prime roles
in metabolic regulation/dysfunction. A search was done on PubMed/Medline, Web of
Science, and Scopus databases using the following keywords: vitamin D, vitamin D
receptor, hydroxylases, subcutaneous adipose tissue, visceral adipose tissue, obesity,
and metabolic dysfunction. Our chapter focuses on human studies on VD status and
expression of VDR and VD activation/inactivation enzymes in SAT and VAT in an obese
environment.
Keywords: obesity, adiposity measures, visceral adipose tissue, subcutaneous adipose
tissue, vitamin D, vitamin D receptor, vitamin D hydroxylation
1. Introduction
Obesity is defined as an excess amount of body fat that may impair health [1] and has been
strongly associated with chronic low-grade or metabolic inflammation characterized by the
activation of inflammatory signaling pathways and abnormal secretion of a large set of immune
response mediators and several bioactive proteins [2, 3] known as adipokines [4] and a deficit
of mediators responsible for the resolution of this process [5]. Within the adipose tissue (AT),
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other cells are also present including preadipocytes, mast cells, and macrophages, which also
contribute to this inflammatory environment. Currently and worldwide, obesity is the fifth
greatest risk factor for mortality [6], and it is associated with vitamin D deficiency (VDD) [7].
Vitamin D (VD) is essential for the development and maintenance of bone tissue, as well as for
normal homeostasis of calcium and phosphorus [8]. Moreover, VD has other major functional
roles; it is related to differentiation, cell proliferation, and hormone secretion. It is an important
nutrient with crucial role in obesity onset (AT) and in the comorbidities associated with the
chronic inflammation [9].
An estimated 80–90% of VD from the human body originates from skin synthesis, with sunlight
activation, while the rest is supplied through supplements or food [10]. VD status is measured
by means of the plasma levels of 25-hydroxyvitamin D [25(OH)D] or calcidiol, the dominant
circulating form and the best indicator of VD status [11]. The action of 1,25(OH)2D, active form
of VD [12], is mediated through the vitamin D receptor (VDR), a member of the nuclear receptor
superfamily, which regulates the transcription of many target genes [13].
The VDR signaling pathway is crucial for the proper functioning of AT that is called an active
endocrine organ, which plays an important role in fat storage and in the production and
secretion of adipokines [14, 15]; is a reservoir for VD; and, besides, can activate/inactivate it by
hydroxylation. VD and VDR are implicated in preadipocyte differentiation into adipocytes
[16].
Major differences between subcutaneous adipose tissue (SAT) and visceral adipose tissue
(VAT) were shown in the expression of VD-metabolizing enzymes. The expression of the VDR,
25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) genes, and 24-hydroxylase enzymes has
been shown in human adipocytes [17].
In line, our chapter will focus on VD status and expression of VDR and VD hydroxylase
enzymes in SAT and VAT in an obese environment.
2. Vitamin D, VDR, and hydroxylase enzymes on adipose tissue
2.1. Vitamin D
VD is a hormone mainly described for its role as a regulator of phosphate and calcium
homeostasis [18, 19], therefore playing an important part in bone metabolism, and seems to
have some anti-inflammatory and immune-modulating properties. This micronutrient can be
obtained through animal (VD3, cholecalciferol) or plant (VD2, ergocalciferol) food sources.
However, vitamin D3 is the only form that is found naturally in human subjects and other
animals. Although the main source of vitamin D3 is through endogenous synthesis in the skin,
the vitamin can also be obtained from the diet, and this is important for those who have limited
exposure to the sun [20].
VD3 is produced endogenously in the skin after UVB irradiation, between 290 and 315 nm,
present for limited number of hours also varying with respect to latitude and reason. VD3 is
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formed from the precursor 7-dehydrocholesterol to give pre-VD3 and further is released into
the circulation [21]. Vitamin D3, whether derived from sunlight or the diet, enters the circula-
tion bound to vitamin D–binding protein (DBP) and is transported to the liver. VD3 is hy-
droxylated in the liver to 25(OH)D, the major circulating vitamin D metabolite; it has a
relatively long half-life (15 days) but, however, is an inactive form. The Institute of Medicine
proposed that serum 25(OH)D concentrations below 50 nmol/l or 20 ng/ml should be consid-
ered to represent the deficiency of this nutrient [22]. 25(OH)D is then further hydroxylated by
1α-hydroxylase enzyme (gene: CYP27B1), and this occurs primarily in the kidney to produce
1,25(OH)2D, the biologically active form of VD [23, 24].
In relation of signaling of VD in AT, 25(OH)D can promote the differentiation of human adi-
pocytes, most likely via its activation to 1,25(OH)2D [25]. The local metabolism of VD in AT
may regulate the conversion of preadipocytes to adipocytes and later support the healthy
remodeling of human AT. Also, 1,25(OH)2D may promote the differentiation of human prea-
dipocytes by maintaining a high expression level of key adipogenic transcription factors, like
C/EBPα and PPARγ gene expression, the two master regulators of adipogenesis that were
increased during the late phase of differentiation [26]. Besides, 1,25-dihydroxyvitamin D
modulates adipogenesis through VDR-dependent inhibition of critical molecular compo-
nents of it such as PPARγ [27].
The emerging role of VD in immune regulation suggests that this endocrine factor can
modulate the inflammatory responses in AT. 1,25(OH)2D displayed an anti-inflammatory effect
and its ability to improve the insulin-stimulated uptake of glucose, as well as enhance and
improve the function of pancreatic β-cell [28]. To strongly support the anti-inflammatory effect
of 1,25(OH)2D in adipocytes, the improvement of pro-inflammatory status and glucose uptake
in adipocytes under 1,25(OH)2D effect suggest that low-grade inflammation could be linked
to VDD [29].
The 1,25(OH)2D significantly reduced the basal release of MCP-1, IL-8, and IL-6 from preadi-
pocytes (MCP-1 is produced by macrophages which increase further macrophage infiltration
into AT [30], and circulating levels of IL-8 are increased in obesity). It should also be pointed
out that since adipocytes store VD, adipocytes and monocytes/macrophages are able to locally
convert 25(OH)D to 1,25(OH)2D [31, 32], and the concentrations of VD within AT could be
higher than implied by the plasma levels. Vitamin D3 may protect against AT inflammation in
obesity by disrupting the deleterious cycle of macrophage recruitment [33].
Lower 25(OH)D is associated with greater regional adiposity; this is stronger in VAT than SAT
and significant across the spectrum of body size [34]. VD has been reported to act as an acute
phase reactant as a consequence of such an inflammatory response occurs in obesity, which
can suppress the concentration of 25(OH)D [35].
2.2. Vitamin D receptor
The human VDR is a 50- to 60-kDa molecule, a member of the nuclear receptor superfamily
that is the only nuclear receptor that binds to 1,25(OH)2D with high affinity and specificity.
VDR forms a heterodimer with the retinoid X receptor acting as a transcription factor that binds
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to VD response elements in the promoter region of target genes [36]. VDR expression has been
identified in most human tissues, including in osteoblasts, skin keratinocytes, macrophages,
smooth muscle, pancreatic β-cells and epithelial cells [37, 38], and it is also highly expressed
in adipocytes.
The action of 1,25(OH)2D is mediated through the VDR, which regulates the transcription of
many target genes [13]. There are more than 1000 genes that are directly or indirectly regulated
by 1,25(OH)2D and involved in various physiological processes such as cell proliferation,
differentiation, apoptosis, and angiogenesis [38].
VDR expression is increased in obese, which has more VAT than lean subjects, but the
physiological relevance of this upregulation has not yet been elucidated. VAT VDR gene
expression correlated positively with body mass index (BMI) [39]. The ubiquitous expression
of VDR may underlie the diverse effects of VD and provide a mechanistic basis for the link
between VDD and a number of disorders that are linked with obesity like certain types of
cancer, inflammatory bowel disease, cardiovascular diseases (CVD), diabetes (type 1 and type
2), and the metabolic syndrome [40–42].
Expanding to another approach, there are associations of VDR variants with the more met-
abolically active fat, VAT, which is more closely tied to the metabolic consequences of
adiposity. Association of VDR SNP rs4,328,262 with VAT supports the notion that the VDR
gene is likely to be related to the development of obesity and obesity-related outcomes [43].
Polymorphisms in the VDR gene might play a role in regulating AT activity body fatness
and susceptibility to adiposity among African Americans, albeit genetic factors that con-
tribute to adiposity are certainly more complex than to be explained totally by variations in
a single gene.
2.3. Hydroxylase enzymes
The formation, activation, and catabolism of 25(OH)D are complex processes, which involve
mitochondrial and microsomal cytochrome P450 enzymes. In humans, four cytochrome P450
enzymes, CYP2R1, CYP3A4, CYP27A1, and CYP2J2, [44–47] possess 25-hydroxylase activity,
with CYP2R1 being the most specific. Hydroxylation in the 1α-position is effected by the
mitochondrial CYP27B1. This process was classically located to the kidney, but recently,
extrarenal 1α-hydroxylase activity has been described in several other tissues [48]. 1,25(OH)2D
stimulates its own degradation by induction of the 24-hydroxylase (CYP24A1), which
catabolizes 25(OH)D and 1,25(OH)2D to calcitroic acid and other inactive metabolites [49].
2.3.1. 25-Hydroxylation
Various enzymes may be associated with the first hydroxylation of 25(OH)D, but CYP2R1
seems to be the key to this hydroxylation [50]. In humans, other cytochromes P450 such as
CYP3A4, CYP27A1, and CYP2J2 show activity of 25-hydroxylase to vitamin D molecules but
less efficient. CYP2J3, CYP2D25, and CYP2C11 also show activity of 25-hydroxylase but are
only expressed in male pigs and rats, respectively [51]. 25-Hydroxylation appears to be
functional in AT. Interestingly, in human AT, biopsies have confirmed the expression of
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CYP27A1, CYP2R1, and CYP2J2, suggesting that human AT and adipocytes are able to convert
vitamin D3 into 25(OH)D.
2.3.2. 1α-Hydroxylation
25(OH)D is then secreted into the circulation or directed to 1α-hydroxylase CYP27B1 mito-
chondria to be metabolized to 1,25(OH)2D. CYP27B1 is the key enzyme 1α-hydroxylation, and
its activity is regulated by the parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23),
calcium, and phosphorus and self-regulated by 1,25(OH)2D via negative feedback mechanism
[18]. CYP27B1 mRNA, which encodes the 1α-hydroxylase that converts 25(OH)D to the
biologically active 1,25(OH)2D, was present at significant levels in SAT and VAT. This gene was
mainly expressed in the stromal vascular fraction of human AT that contains preadipocytes,
macrophages, and endothelial cells. The expression of CYP27B1 has also been detected in
adipocytes of murine [17] and human AT biopsies [52].
2.3.3. 24-Hydroxylation
Vitamin D 24-hydroxylase (CYP24A1) is responsible for the inactivation of 1,25(OH)2D. This
inactivation is self-regulated, from 1,25(OH)2D induces the expression of CYP24A1 which
converts 25(OH)D in 1,25(OH)2D within the less active metabolites (24,25(OH)2D and
1,24,25(OH)3D), which are later catabolized into inactive calcitroic acid [53]. In AT, the
expression of CYP24A1 has been detected in murine and human adipocytes. Additionally,
levels of CYP24A1 mRNA are strongly induced by incubation of 1,25(OH)2D.
The expression of 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) genes and 24-hydroxylase
enzyme has been shown in human adipocytes [17]. The CYP24 gene, which encodes the
enzyme catalyzing 1,25(OH)2D, was also found to be expressed by human adipocytes and
preadipocytes [31, 54]. Recently, a low expression of CYP27B1 gene in SAT of obese individuals
has been shown [52]; this finding corroborates the ability of AT to metabolize VD locally. One
of the main mechanisms by which this vitamin may act in human AT is via the expression of
VD-metabolizing enzymes such as 25-hydroxylase CYP2J2, CYP27B1, and CYP24 [55]. This
capacity to metabolize VD locally was demonstrated when, after weight loss in obese subjects,
plasma 25(OH)D increased and expression levels of 25-hydroxylase CYP2J2 and 1α-hydrox-
ylase CYP27B1 declined in the SAT of these subjects. So, a dynamic alteration may occur in AT
during weight loss and obesity.
In the SAT of the obese individuals have a lower expression of one of the enzymes responsible
for 25-hydroxylation of VD (CYP2J2), as well as a tendency toward a decreased expression of
the 1α-hydroxylase, 25-hydroxylation and the 1α-hydroxylation in SAT are impaired in obesity
AT expresses the enzymes for both the formation of 25(OH)D and of 1,25(OH)2D, and for
degradation of VD. To explain an altered VD metabolism in obesity, major differences between
SAT and VAT in the expression of VD-metabolizing enzymes occur with difference in spread-
ing between lean and obese subjects [52]. The expression of CYP27A1 is more pronounced in
VAT than in SAT, without differences between lean and obese women, while the expression of
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CYP2J2 is more prominent in SAT than in VAT in lean women. So, these findings lead to a
compromised of 25-hydroxylation in SAT in obese, taken by a lower expression of the CYP2J2.
3. Mechanisms suggested for VDD in obesity
Several studies have shown the relationship between obesity and inadequacy of VD [56–58].
Evidence suggests that one of the VDDs in subjects with obesity may be connected to storage
of VD in the adipocytes, reducing its bioavailability and activating the hypothalamus to
develop a cascade of reactions that result in increased feelings of hunger and decreased energy
expenditure [59]. Low serum of 25(OH)D concentrations is found to be inversely correlated
with measures of obesity, including body mass index (BMI) (≥30kg/m2), fat mass, and WC [60,
61]. A bidirectional genetic study has suggested that higher BMI chiefs to lower 25(OH)D;
each unit increase in BMI is being associated with 1.15% lower concentration of 25(OH)D,
after adjusting for age, sex, laboratory collection, and month of measurement [62]. The
relationship between obesity and 1,25(OH)2D is less clear, and this is probably due to the
dynamic nature of the production and regulation of the active hormone. However, the study
in vitro showed that 1,25(OH)2D acts as a potent inhibitor of leptin secretion in a culture of
human adipocytes [63].
Extensive evidence has demonstrated that adipocytes become enlarged and dysregulated the
following weight gain, which subsequently produces an imbalance in the inflammatory profile
of AT. So, obesity is commonly linked to an upregulation of pro-inflammatory molecules and
downregulation of anti-inflammatory molecules [64]. Individuals with both high SAT and high
VAT have an approximately threefold prevalence of VDD compared with those with both low
SAT and low VAT [34]. A predominant effect of VD on macrophages could explain the
differences observed in relations of VD response in VAT versus SAT. Is observed a greater
macrophage infiltration of VAT when compared with SAT in individuals with obesity. In
contrast, inflammatory markers in AT strongly correlate with macrophage infiltration [65], and
many metabolic differences could potentially explain the different VD-induced anti-inflam-
matory response observed between these two types of AT, including the number of cells
expressing the VDR [52]. Because ATs of obese are infiltrated with macrophages, it seems likely
that macrophages also contribute to the local activation of VD. Because SAT and BMI are closely
correlated, it is possible that most of the association between SAT and 25(OH)D is attributable
to the difference in body size that is seized by BMI. It is observed that lower 25(OH)D was
associated with greater regional adiposity.
In fact, the basis of low concentration in subjects with obesity is not totally known but could
be the result of various mechanisms. There are five suggested mechanisms that are most
commonly cited within the literature which may explain a low VD status in obesity:
• Obese individuals have reduced sun exposure compared with lean subjects.
• Low 1.25(OH)2D inhibits adipogenesis.
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• Negative feedback control.
• Vitamin D is sequestered within adipose tissue.
• Lower 25(OH)D concentration is just due to volumetric dilution.
3.1. Reduced sun exposure
Obese individuals reduce their exposure to sunlight, reportedly have a limited mobility, avoid
performing outdoor activities, and/or use clothes that cover more of the body [56], which limit
exposure to the sun and, consequently, cutaneous VD synthesis. However, in a study based on
the Framingham cohort, which evaluated the association between obesity and VD, it was
reported that after adjustments for practicing outdoor physical activities, this theory was
insufficient to explain the relationship between obesity and VDD [34]. In addition, the study
indicates that daily exposure to 0.5 standard erythemal dose (SED) between 11:00 and 13:00h,
using typical summer clothing, was not enough to achieve the state suitable of VD in the late
summer [66]. Until now, it is still unclear which VD supplementation dose corresponds to the
amount of UVB radiation exposed, in regard to efficiency to increase serum concentrations of
25(OH)D and as little establishing a standard exposure solar time daily necessary to achieve
an adequate state of VD [67].
3.2. Low 1.25(OH)2D inhibits adipogenesis
Some experimental data have suggested that VDD can favor greater adiposity by promoting
increased PTH hormone levels and greater inflow of calcium into adipocytes, so increasing
lipogenesis [68]. Evidence suggests that low 1.25(OH)2D inhibits adipogenesis through actions
modulated by vitamin D-dependent receptors [69]. Thus, depletion of vitamin D can lead to
excessive differentiation of preadipocytes to adipocytes.
3.3. Negative feedback control
Excess AT impairs the VD status from activating energy expenditure. In this mechanism, the
leptin stimulates osteocytic FGF23, inhibits renal synthesis of 1α-hydroxylase, and conse-
quently impairs the production of 1,25 (OH)2D, creating a negative feedback mechanism [70].
3.4. Sequestration in adipose tissue
Wortsman et al. [71] published the first study to provide strong convincing evidence that VD
(as a fat-soluble vitamin) may become sequestered within AT. In their study, the concentration
of circulating cholecalciferol was similar between obese and lean groups at baseline, but the
obese group had a significantly reduced response to the UVB intervention, resulting in a 57%
lower serum cholecalciferol concentration postintervention, compared with the control group
(lean). This suggested that the limitation in the obese group was the bioavailability of the
synthesized cholecalciferol in circulation [71]. This sequestration theory is probably the most
supported in the literature.




Most recently, Drincic et al. [72] showed that body weight and body fat are inversely correlated
with 25(OH)D levels across the spectrum of body weight ranging from normal to obese. This
inverse association is related to the greater volume of distribution for both VD3 and 25(OH)D
in tissue mass. They suggested that simple volumetric dilution is the most thrifty explanation
for the low VD status in obesity. A hyperbolic model best explains the lower 25(OH)D values
in obesity, and when serum 25(OH)D values was adjusted for body weight, difference between
obese and normal subjects disappeared. These authors went on to recommend that the VD
dosing for treatment of VDD in obesity should be based on body weight, for example, “one
size does not fit all” [72].
Overall, although these are the five most commonly suggested mechanisms, the latter two
theories have more robust evidences available. The strong evidence presented for the seques-
tration and volumetric dilution hypotheses, and more importantly, a lack of contradictory
evidence for either, suggest that they are the most probable, independently or in combination,
to explain the low VD status widely reported in obesity.
4. Conclusions
The prevalence of obesity and VDD is growing exponentially in recent decades, and several
studies have been conducted worldwide, particularly, the signs of VDR and hydroxylase
enzymes in AT (SAT and VAT). VD is a nutrient with important role in the genesis of obesity
and also in diseases associated with chronic inflammation. It features an anti-inflammatory
effect in AT, anti-adipogenic activity, exerts immunoregulatory effect, and has the capacity to
limit the expression of inflammatory markers in AT. Scientific evidences suggest that AT is a
target for VD action, as CYP27B1 and VDR genes that are expressed by adipocytes. All evidence
suggests that 25(OH)D, 1,25(OH)2D, and VDR are involved in the AT, through the endocrine
system as well as autocrine/paracrine actions of VD.
Based on news researches, there is a hypothesis that AT is not only a stock of VD but also has
a dynamic ability to activation and deactivation of this vitamin in obesity. Low VD status in
obesity may have implications for AT biology based on recent data from different research
groups which are converging to highlight the impacts of VD on AT/adipocyte biology.
Therefore, some key points have yet to be elucidated in relation to VD metabolism and its
regulation on AT, especially in obese environment.
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